Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,557.00+0.95%ETH$2,485.53+0.45%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
SC

NASDAQ · SCYX

SCYNEXIS, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$4.22

Down-$0.14 (-3.32%)

Updated Oct 9, 2026, 11:17 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
27.27M
P/E ratio
-1.66
Dividend yield
0.00%
52-week range
$0.63 – $6.16
Volume
344.03K
Avg. volume
560.01K

Price performance · SCYX

SCYX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

SCYX closed at $4.22 after 21 trading sessions, down 10.21% for the selected period.

Last close
$4.22
Period change
-10.21%
Period low
$4.11
Period high
$5.37
Daily close
View OHLC price history
SCYX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$4.70$4.75$4.11$4.22344.03K
Oct 7, 2026$4.86$5.04$4.75$4.7880.84K
Oct 6, 2026$5.10$5.29$4.79$4.84163.95K
Oct 5, 2026$5.09$5.20$4.83$5.03356.47K
Oct 2, 2026$5.32$5.51$5.09$5.12132.4K
Oct 1, 2026$4.99$5.50$4.86$5.37601.97K
Sep 30, 2026$4.65$5.025$4.56$4.94311.61K
Sep 29, 2026$4.62$4.80$4.5201$4.66542.39K
Sep 28, 2026$4.60$5.14$4.45$4.627.78M
Sep 25, 2026$4.582$4.582$4.3662$4.3931.64K
Sep 24, 2026$4.58$4.81$4.415$4.4538.02K
Sep 23, 2026$4.93$5.00$4.42$4.63565.73K
Sep 22, 2026$4.47$4.9399$4.36$4.86167.83K
Sep 21, 2026$4.59$4.59$4.27$4.4045.91K
Sep 18, 2026$4.49$4.695$4.41$4.4668.81K
Sep 17, 2026$4.11$4.59$4.11$4.4570.98K
Sep 16, 2026$4.43$4.5328$4.08$4.11102.8K
Sep 15, 2026$4.59$4.63$4.37$4.3964.47K
Sep 14, 2026$4.84$4.97$4.572$4.6047.61K
Sep 11, 2026$4.72$5.0586$4.72$4.8430.45K
Sep 10, 2026$4.82$4.97$4.63$4.7047.34K

Latest SCYX news

The latest Smart Investors Daily articles mentioning SCYX.

Stock researchCompany · Overview

SCYX research

Overview

Company profile and research snapshot.

Company profile

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SCYX recent ratings
DateFirmRatingTarget
Aug 13, 2026GuggenheimBuy—
Oct 28, 2025GuggenheimBuy—
Apr 1, 2024Cantor FitzgeraldOverweight—
Aug 15, 2023Cantor FitzgeraldOverweight—
Apr 3, 2023GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 28, 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247

Yahoo · Jan 21, 2026

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By